New medication lowers triglyceride levels, yet does not decrease cardiovascular risk in people with Type 2 diabetes

A new medication, pemafibrate, lowered triglyceride levels among adults with Type 2 diabetes yet did not decrease their cardiovascular risk, according to late-breaking science research presented today at the American Heart Association’s Scientific Sessions 2022.